Eli Lilly and Company (LLY)
Eli Lilly's (LLY) diabetes injection Mufenda gets approval in China
Eli Lilly and Company announced on Tuesday that the National Medical Products Administration (NMPA) in China has approved the distribution of its injection Mufenda. This injection is designed to treat diabetes, improve blood sugar control, and aid in weight loss for adults with type 2 diabetes.
Eli Lilly's diabetes drug tirzepatide gets approval in China
Eli Lilly said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, setting up intensifying competition with its Danish rival Novo Nordisk in the key Asian market.
Here's How Much $100 Invested In Eli Lilly and Co 5 Years Ago Would Be Worth Today
Eli Lilly and Co LLY has outperformed the market over the past 5 years by 32.88% on an annualized basis producing an average annual return of 46.32%. Currently, Eli Lilly and Co has a market capitalization of $744.41 billion. Buying $100 In LLY: If an investor had bought $100 of LLY stock 5 years ago, it would be worth $670.53 today based on a price of $783.25 for LLY at the time of writing. Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by an editor. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Pharma Stocks Outlook: Where Are 2024's Top Performers Headed Next?
The three top performing stocks discussed below have appreciated in value by an average of 129.7% in 2024. Such torrid growth logically raises the question of what is possible moving forward.
Eli Lilly's (LLY) Efsitora Matches Daily Insulins in A1C Control
Eli Lilly's (LLY) two phase III studies on its once-weekly insulin, efsitora alfa, meet their primary endpoint of non-inferior reduction in blood sugar levels compared with daily basal insulins.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
3 Drug Stocks to Watch on Raised 2024 Earnings & Sales Guidance
Here we discuss three drugmakers, Eli Lilly and Company (LLY), Novo Nordisk (NVO) and Merck (MRK), that have raised their earnings as well as sales guidance for 2024.
